At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 166 enrolled
Drug / intervention
ombitasvir/paritaprevir/ritonavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)
In Brief
A Phase 3 clinical trial evaluating ombitasvir/paritaprevir/ritonavir and dasabuvir for Hepatitis C Infection and Hepatitis C Virus. Completed, enrolled 166 participants.
Detailed Summary
This study will evaluate the safety and efficacy of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b (GT1b) hepatitis C virus (HCV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Infection, Hepatitis C Virus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartNov 2015
Primary CompletionAug 2016
Study CompletionDec 2016
TodayJul 2026
First PostedOct 21, 2015
Enrollment StartNov 24, 2015
Primary CompletionAug 24, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.7 years ago
Interventions
ombitasvir/paritaprevir/ritonavirdrug
Tablet
dasabuvirdrug
Tablet